Predictors of Post-Thrombectomy Cognitive Impairment in Acute Ischemic Stroke Patients

November 17, 2025 updated by: Mohammad Ahmad Mohammad Korayem, Assiut University

Predictors of Post-Thrombectomy Cognitive Impairment in Acute Ischemic Stroke Patients : a Prospective Cohort Study

This prospective cohort study investigates predictors of post-stroke cognitive impairment (PSCI) in patients undergoing endovascular thrombectomy (EVT) for acute ischemic stroke due to large vessel occlusion. Adult patients with successful reperfusion (mTICI 2b-3) will be followed at 3 and 6 months to assess cognition, functional recovery, and depression. Predictors across clinical, procedural, radiological, and laboratory domains will be analyzed. The study aims to identify risk factors for PSCI, estimate its prevalence, and evaluate its impact on outcomes.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

Post-stroke cognitive impairment (PSCI) is a major cause of long-term disability, affecting up to 40% of ischemic stroke survivors. Large vessel occlusion (LVO) strokes, often treated with endovascular thrombectomy (EVT), carry a particularly high risk of cognitive sequelae. While EVT has proven efficacy in improving functional outcomes, its effect on cognitive outcomes remains underexplored.

This prospective observational cohort study will enroll approximately 120 adult patients (≥18 years) with anterior circulation LVO undergoing EVT at Assiut University Hospital. Eligible participants must achieve successful reperfusion (mTICI 2b-3) and provide consent. Patients with severe aphasia, coma, pre-existing dementia, non-ischemic etiologies, or early death (within 72 hours) will be excluded.

Participants will undergo systematic assessment of cognitive function (MoCA-Arabic, Oxford Cognitive Screening if MoCA <26), functional status (mRS, Barthel Index), and mood (HADS-Arabic) at baseline, 3 months, and 6 months. Clinical data (demographics, vascular risk factors, NIHSS, time metrics), procedural details (technique, procedure time, number of passes, anesthesia type, hemodynamic stability, complications), radiological parameters (infarct site and volume, ASPECTS, WMH by Fazekas score, cortical atrophy, microbleeds), and laboratory markers (CRP, ESR, lipid profile, HbA1C, uric acid, D-dimer, CBC) will be collected.

The primary objective is to identify predictors of PSCI at 3-6 months after thrombectomy. Secondary objectives include estimating the prevalence of PSCI in this population and analyzing its association with functional outcomes and depression. Statistical analysis will include univariate and multivariate regression models adjusting for potential confounders such as age, education, and infarct volume.

Ethical approval has been obtained from the Faculty of Medicine, Assiut University Ethics Committee. Written informed consent will be obtained from all participants, and confidentiality will be strictly maintained.

Study Type

Observational

Enrollment (Estimated)

120

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Probability Sample

Study Population

As described in inclusion/exclusion criteria

Description

Inclusion Criteria:

  1. Adults (≥18 years).
  2. Acute ischemic stroke due to anterior circulation LVO confirmed by imaging undergoing EVT per guidelines.
  3. Successful reperfusion (mTICI 2b-3)
  4. Able to provide consent.

Exclusion Criteria:

  1. Severe aphasia/coma interfering with cognitive assessment.
  2. Pre-existing dementia ( using Arabic version of the Short Form of the Informant Questionnaire on Cognitive Decline in the Elderly).
  3. Non-ischemic etiology.
  4. Death within 72 hours.
  5. Refusal to participate in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Postthrombectomy
All patients wgo underwent endovascular thrombectomy under standard care will be assessed for cognitive function at 3 time points

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cognitive impairment after thrombectomy (MoCA)
Time Frame: 3 months (±2 weeks) and 6 months (±2 weeks) post-thrombectomy
Cognitive status will be assessed using the Arabic version of the Montreal Cognitive Assessment (MoCA, score range 0-30, with scores <26 indicating impairment). The primary outcome will be the prevalence of post-stroke cognitive impairment (PSCI) among thrombectomy patients.
3 months (±2 weeks) and 6 months (±2 weeks) post-thrombectomy

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Domain-specific cognitive performance (OCS)
Time Frame: 3 months (±2 weeks) and 6 months (±2 weeks) post-thrombectomy
For participants scoring <26 on MoCA, the Oxford Cognitive Screen (OCS) will be administered to evaluate specific domains of cognition (attention, executive function, memory, language, visuospatial ability).
3 months (±2 weeks) and 6 months (±2 weeks) post-thrombectomy
Depression and anxiety symptoms (HADS)
Time Frame: 3 months (±2 weeks) and 6 months (±2 weeks) post-thrombectomy
Psychological status will be measured using the Hospital Anxiety and Depression Scale (HADS, score range 0-21 per subscale). Outcomes will include mean scores and prevalence of clinically significant symptoms.
3 months (±2 weeks) and 6 months (±2 weeks) post-thrombectomy
Functional independence (Barthel Index)
Time Frame: 3 months (±2 weeks) and 6 months (±2 weeks) post-thrombectomy
Functional status will be assessed using the Barthel Index (score range 0-100). Higher scores indicate greater independence in activities of daily living.
3 months (±2 weeks) and 6 months (±2 weeks) post-thrombectomy
Global disability (modified Rankin Scale)
Time Frame: 3 months (±2 weeks) and 6 months (±2 weeks) post-thrombectomy
Global disability will be measured using the modified Rankin Scale (mRS, score range 0-6, with 0 indicating no symptoms and 6 indicating death).
3 months (±2 weeks) and 6 months (±2 weeks) post-thrombectomy
Infarct volume (DWI MRI)
Time Frame: Within 24-72 hours post-thrombectomy
Infarct size will be quantified using diffusion-weighted MRI, measured in milliliters.
Within 24-72 hours post-thrombectomy
White matter hyperintensity (Fazekas score)
Time Frame: Within 24-72 hours post-thrombectomy
White matter disease burden will be assessed using the Fazekas score (0-3 scale) on FLAIR MRI
Within 24-72 hours post-thrombectomy
CRP
Time Frame: Within 24-72 hours post-thrombectomy
C-reactive protein (CRP, mg/L)
Within 24-72 hours post-thrombectomy
Lipid profile
Time Frame: Within 24-72 hours post-thrombectomy
lipid profile (mg/dL)
Within 24-72 hours post-thrombectomy
Ddimer
Time Frame: Within 24-72 hours post-thrombectomy
D-dimer (µg/mL)
Within 24-72 hours post-thrombectomy

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2025

Primary Completion (Estimated)

December 30, 2027

Study Completion (Estimated)

January 15, 2028

Study Registration Dates

First Submitted

September 19, 2025

First Submitted That Met QC Criteria

November 17, 2025

First Posted (Actual)

November 19, 2025

Study Record Updates

Last Update Posted (Actual)

November 19, 2025

Last Update Submitted That Met QC Criteria

November 17, 2025

Last Verified

September 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • CogEVT25

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.